Argos Therapeutics (ARGS) Stock Price Down 5.9%

Argos Therapeutics, Inc. (NASDAQ:ARGS) shares were down 5.9% on Wednesday . The stock traded as low as $0.16 and last traded at $0.16. Approximately 1,820,596 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 2,388,278 shares. The stock had previously closed at $0.17.

Separately, Zacks Investment Research cut Argos Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have given a hold rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $4.13.

The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.

An institutional investor recently bought a new position in Argos Therapeutics stock. Wasatch Advisors Inc. purchased a new stake in shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Argos Therapeutics (ARGS) Stock Price Down 5.9%” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

What are top analysts saying about Argos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Argos Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit